Ass. Prof Montana and her team are working on developing a registry and growth charts for patients with MPS IVA and are in pre-clinical trials for enzyme replacement therapy for patients affected by MPS IVA. They are also developing a bone targeting system for treatment of MPS disorders, substrate reduction therapy for MPSs, and gene therapy for MPS IVA. Other areas of interest are characterisation of hyaluronidases, the molecular evolution of glycosaminoglycans and peptidoglycan receptor proteins, and chondroitin sulfate metabolism.